The Pfizer/ University College London (UCL) collaboration brings together the pioneering work of university researchers in the field of cell-based therapies and Pfizer’s expertise in the design and delivery of therapeutics, said Pfizer.
Pfizer’s contributions will include expertise in the design and execution of clinical studies and interaction with global regulators as well as in product manufacturing techniques.
The collaboration will examine how human embryonic stem cells differentiate into retinal pigment epithelium (RPE) with the goal of developing stem cell-based therapies primarily for wet and dry macular degeneration.
Under the terms of the agreement, Pfizer will provide funding to UCL to enable research into the development of stem cell-based therapies for age-related macular degeneration as well as other retinal diseases. Pfizer is granted exclusive worldwide rights to develop and commercialize an RPE stem cell-based therapeutic in the ophthalmology field. After the completion of preclinical safety studies, Pfizer will have the option to conduct clinical trials to determine efficacy of treatment and commercialize any resulting product.
Ruth McKernan, chief scientific officer of Pfizer Regenerative Medicine, said: “We are excited to be working with pioneers in the field of stem cell ophthalmology from UCL. While we have much to learn about how stem cells can be used therapeutically, we are confident that this relationship will increase that understanding and help us advance to a time when our work may benefit patients worldwide.”